Post by
Viking2233 on Feb 26, 2024 8:05am
Management Credibility
is on the line this week. My fingers are crossed that we announce first dosing on or before Feb 29, 2024. If first dosing is not announced it will be a major setback for management. I truly am perplexed that this has not happed yet considering they got final Turkish approval 10 weeks ago and have been planning the AKI phase 2 trial for 2 years.
Remember first dosing was initially announced to commence Fall of 2023. It was then delayed until Feb 2024. No communication to explain the delay.
They have until Thursday to achieve their revised target date, the question is will they?
My fingers are crossed but my frustration with this management team hitting dates they announce are becoming a going concern coupled with their lack of communication to the markets.
Dont forget they still have not released third party peer review for Lung phase 2 trial from 2 years ago. It was announced they would release no later then June 30, 2023, so we are 8 months past due. This data is crucial to get our sole analyst from Raymond James back on side and potentially some institutional interest.
I was anxiously hoping I would see positive news this morning but nothing at the time of writing.
Long and strong on science but luke warm on this management and execution.